Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Interest & Investment Income: 2021-2025

Historic Interest & Investment Income for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to $1.8 million.

  • Amylyx Pharmaceuticals' Interest & Investment Income fell 41.22% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 47.50%. This contributed to the annual value of $13.8 million for FY2024, which is 14.52% down from last year.
  • Amylyx Pharmaceuticals' Interest & Investment Income amounted to $1.8 million in Q3 2025, which was down 7.09% from $2.0 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Interest & Investment Income high stood at $4.4 million for Q4 2023, and its period low was $1,000 during Q2 2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Interest & Investment Income value was $3.7 million (recorded in 2023), while the average stood at $3.3 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Interest & Investment Income spiked by 40,100.00% in 2022 and then plummeted by 51.83% in 2025.
  • Amylyx Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $30,000 in 2021, then soared by 10,423.33% to $3.2 million in 2022, then surged by 38.45% to $4.4 million in 2023, then crashed by 47.01% to $2.3 million in 2024, then tumbled by 41.22% to $1.8 million in 2025.
  • Its Interest & Investment Income was $1.8 million in Q3 2025, compared to $2.0 million in Q2 2025 and $2.2 million in Q1 2025.